Category: Multiple Sclerosis

A specialised non-invasive imaging technique has detected metabolic abnormalities in areas of brain white matter that appeared normal on conventional MRI scans in people with early relapsing-remitting multiple sclerosis (RRMS). The study, published in Acta Neurologica Belgica, investigated whether proton magnetic resonance spectroscopy (1H-MRS) could identify subtle abnormalities that may not be visible using standard…

Real-world data from more than 6,500 people with relapsing-remitting multiple sclerosis suggest that Ocrevus and Kesimpta provide similarly strong disease control, although researchers identified small differences in relapse and disability outcomes. The international study analysed registry data from 6,572 adults with relapsing-remitting MS who started treatment with either ocrelizumab (Ocrevus) or ofatumumab (Kesimpta) between 2021…

A real-world study has found that two widely used disease-modifying therapies, anti-CD20 treatments and sphingosine-1-phosphate (S1P) receptor modulators, provide similar clinical benefits for most people with late-onset multiple sclerosis (LOMS). Researchers analysed data from 447 adults with relapsing-remitting MS enrolled in the international MSBase registry whose symptoms began after the age of 50. Participants had…

Cannabis-based therapies, particularly products combining tetrahydrocannabinol (THC) and cannabidiol (CBD), may provide modest relief from spasticity in people with multiple sclerosis (MS), according to a systematic review of 27 randomised clinical trials involving more than 3,000 participants. Published in the British Journal of Clinical Pharmacology, the review found that preparations containing both THC and CBD,…

A large international study suggests that even a single clinically silent MRI lesion may identify people with relapsing-remitting multiple sclerosis (RRMS) who are at increased risk of future relapses and disability worsening. The findings, published in Brain, challenge current approaches that generally reserve treatment escalation for patients who develop multiple new lesions. Clinically silent lesions…

Researchers have identified six proteins that could become future therapeutic targets for slowing progression in multiple sclerosis (MS), raising the possibility of developing new treatments or repurposing existing medicines for progressive disease. Published in the Journal of Neuroinflammation, the study combined large-scale genetic and protein data to identify biological pathways linked to disability progression in…

Researchers have developed an explainable artificial intelligence (AI) model capable of predicting future cognitive decline in people with multiple sclerosis (MS) with around 90% accuracy, offering a potential new tool to support earlier intervention and more personalised patient care. Published in the European Journal of Neurology, the study combined MRI brain scans with clinical and…

Two new research projects are investigating whether the hormonal and biological changes associated with menopause influence the progression of multiple sclerosis (MS), with the aim of helping clinicians deliver more personalised care for women during midlife. Funded by the National Multiple Sclerosis Society, the complementary studies will examine both the biological changes linked to reproductive…

Briumvi led to fewer relapses, less MRI activity and better disability improvement than Aubagio when used as the first disease-modifying therapy for relapsing multiple sclerosis, according to a new post-hoc analysis of the phase 3 ULTIMATE I and II trials. The analysis focused on 722 participants who had not previously received an approved disease-modifying therapy,…